 Strategic Transaction Provides 7.5M in Non-Dilutive Capital and Enables Pediatric and ADHD Product Focus Following the Recently Closed Merger with Neos Therapeutics ENGLEWOOD, CO ACCESSWIRE April 1, 2021 Aytu BioPharma, Inc. NASDAQ:AYTU a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announced the signing of an agreement with Acerus Pharmaceuticals Corporation ASPASPCF whereby Acerus will acquire all remaining rights to Natesto in the United States from Aytu. In consideration, Aytu will receive 7.5M in cash from Acerus, which is payable in 250,000 monthly payments over 30 months. 